CA
DXCM icon

Clearstead Advisors’s DexCom DXCM Stock Holding History

Clearstead Advisors’s Portfolio DXCM Stock Details DXCM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$103K Buy
1,529
+695
+83% +$46.3K ﹤0.01% 1284
2026
Q1 		$52.4K Sell
834
-3,663
-81% -$255K ﹤0.01% 1271
2025
Q4 		$298K Buy
4,497
+2,653
+144% +$172K ﹤0.01% 822
2025
Q3 		$124K Sell
1,844
-817
-31% -$64.7K ﹤0.01% 996
2025
Q2 		$232K Buy
2,661
+1,883
+242% +$148K ﹤0.01% 849
2025
Q1 		$53.1K Sell
778
-428
-35% -$34.9K ﹤0.01% 1159
2024
Q4 		$93.8K Sell
1,206
-129
-10% -$9.55K ﹤0.01% 1041
2024
Q3 		$89.5K Sell
1,335
-675
-34% -$55.4K ﹤0.01% 1058
2024
Q2 		$228K Buy
2,010
+184
+10% +$23.3K ﹤0.01% 783
2024
Q1 		$228K Buy
1,826
+19
+1% +$2.39K 0.01% 447
2023
Q4 		$224K Buy
1,807
+50
+3% +$5.11K 0.01% 442
2023
Q3 		$164K Sell
1,757
-60
-3% -$6.76K 0.01% 455
2023
Q2 		$234K Buy
1,817
+1,235
+212% +$149K 0.01% 410
2023
Q1 		$67.6K Buy
582
+48
+9% +$5.37K ﹤0.01% 592
2022
Q4 		$60.5K Buy
534
+52
+11% +$5.71K ﹤0.01% 598
2022
Q3 		$39K Hold
482
– – ﹤0.01% 657
2022
Q2 		$36K Buy
482
+50
+12% +$4.56K ﹤0.01% 688
2022
Q1 		$55K Hold
432
– – ﹤0.01% 658
2021
Q4 		$58K Sell
432
-228
-35% -$32.8K ﹤0.01% 632
2021
Q3 		$90K Buy
660
+228
+53% +$28.8K 0.01% 505
2021
Q2 		$46K Hold
432
– – ﹤0.01% 570
2021
Q1 		$39K Hold
432
– – ﹤0.01% 580
2020
Q4 		$40K Sell
432
-48
-10% -$4.29K ﹤0.01% 538
2020
Q3 		$49K Buy
480
+80
+20% +$8.36K 0.01% 468
2020
Q2 		$41K Hold
400
– – ﹤0.01% 452
2020
Q1 		$27K Buy
+400
New +$24.9K ﹤0.01% 473

Other funds holding DXCM

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Clearstead Advisors's DXCM Position: Q2 2026 in Review

Clearstead Advisors increased its DexCom (DXCM) stake by 83% in Q2 2026, buying an estimated $46.3K and bringing the position to 1,529 shares worth $103K. The position accounts for ﹤0.01% of the portfolio, ranked #1284.

Clearstead Advisors first reported a position in DXCM in Q1 2020 and has held it in 26 quarters since. The position peaked at $298K in Q4 2025. 973 funds tracked by Wall St. Rank hold DXCM as of Q2 2026.

  • Clearstead Advisors held 1,529 shares of DexCom worth $103K as of Q2 2026.
  • Clearstead Advisors bought 695 DexCom shares in Q2 2026, an estimated $46.3K.
  • DexCom made up ﹤0.01% of Clearstead Advisors's portfolio in Q2 2026, its #1284 holding.
  • Clearstead Advisors first reported a position in DexCom in Q1 2020 and has held it in 26 quarters since.
  • Clearstead Advisors's DexCom position peaked at $298K in Q4 2025.
  • 973 funds tracked by Wall St. Rank held DexCom as of Q2 2026.

Based on Clearstead Advisors's 13F filing for Q2 2026, filed 6 Aug 2026.